Zydus receives USFDA tentative approval for Sugammadex Injection

18 Sep 2022 , 01:32 AM

Zydus Lifesciences announced that its US subsidiary Zydus Pharmaceuticals USA Inc has received tentative approval from the United States Food and Drug Administration USFDA to market Sugammadex Injection USP 200 mg2 mL 100 mgmL and 500 mg5 mL 100 mgmL Single-Dose Vial US RLD Bridion Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery The drug will be manufactured at the groups injectables manufacturing facility at Jarod India Sugammadex Injection had annual sales of USD 772 mn in the United States according to IQVIA MAT July 2022